Pulse of Asia 2022

Speaker's biography and Meeting abstract

Kazuomi Kario, MD, PhD
Professor, Chairman
Division of Cardiovascular Medicine, 
Department of Medicine, 
Jichi Medical University School of Medicine,
Tochigi, Japan
Dr. Kazuomi Kario graduated from Jichi Medical School in 1986. He is currently Professor and Chairman of Cardiovascular Medicine, Jichi Medical University School of Medicine, Japan. 

In 2003, Dr Kario and his team were the first to demonstrate ’morning surge’ in blood pressure (BP) as an independent risk factor for cardiovascular disease (Kario et al. Circulation 2003). He first used ’morning hypertension’ with the definition of morning BP ≥135/85 mmHg, regardless of clinic BP. He is the principal investigator of several clinical studies, such as the Japan Morning Surge-Home Blood Pressure (J-HOP); Japan Ambulatory BP Monitoring (JAMP); Home-activity ICT-based Japan Ambulatory Blood Pressure Monitoring Prospective (HI-JAMP); Sleep BP and disordered breathing in REsistant hypertension And cardiovascular Disease (SPREAD).

He is serving as Editor-in-Chief of Hypertension Research and Current Hypertension Reviews. He is an editorial board member of more than 15 international journals including Hypertension, Journal of Hypertension. Professor Kario has published more than 1000 academic papers during his distinguished career. He founded the Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia Network)” in 2018.

Meeting abstract

Vascular session:
Lecture title:
The Coupling Registry, a nationwide Cardiovascular Prognostic Coupling Study, and latest evidence in Japan
Kazuomi Kario
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan

Last year, 12 Japanese and US experts in vascular function and hypertension, including Matthew J. Budoff et al. from UCLA, 10 from the US, and 2 from Japan, compiled a consensus on the clinical application of CAVI. A consensus was reached on the clinical application of CAVI. In our recent study using the AI demonstrated that CAVI is the independent predictor of hypertension (Kanegae, Kario, et al. J Clin Hypertens. 2020; 22: 445-450). The results of the CAVI-J study, which examined the event-predictive ability of CAVI in Japanese patients with cardiovascular risk factors clearly indicated high CAVI value is an independent risk for cardiovascular disease, especially heart failure and stroke (Miyoshi et al. J Am Heart Assoc. 2021;10(16):e020103.) The Jichi Medical University Coupling-J] Jichi Medical University is now conducting a nationwide Cardiovascular Prognostic Coupling Study in Japan (Coupling Registry) study to examine changes in CAVI and cardiovascular prognosis over time. This study is a prospective, observational study of Japanese outpatients with any cardiovascular risk factor and has enrolled 5109 patients from 30 centers since 2015 (Kario et al. J Clin Hypertens (Greenwich). 2020 Mar;22(3):465-474). Examination of baseline data showed that high triglycerides and diabetes/abnormal glucose tolerance were associated with CAVI (Kabutoya et al. J Clin Hypertens 2020;22:1208-1215; Sekizuka et al. Int Heart J. 2021;62(6):1320-1327.) Prognosis is currently being followed. In this seminar, we will present the latest findings and consensus on CAVI, an index of vascular stiffness.
Heart Failure session:
Lecture title:
ARNI to break the chain of hypertension, development of cardiac hypertrophy, and onset of heart failure in Asia
Kazuomi Kario
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan

Hypertension is a prominent risk factor for cardiovascular death, and its management is important. However, only about one-fourth of hypertension patients are adequately managed, making it an important issue to educate the public. Recently, the STEP study was reported from China, which reaffirmed the importance of antihypertensive treatment in Asian patients and suggested that it is particularly effective in preventing the onset of heart failure. We have reported that nocturnal hypertension can be a residual risk for heart failure even when blood pressure is controlled over a 24-hour period (Kario et al, Circulation 2020;142:1810-1820) and have proposed the presence of nocturnal hypertension as an important factor linking hypertension and heart failure (Kario K, Williams B. Hypertension 2021;78:564-577). In addition, a new antihypertensive drug, ARNI (angiotensin receptor neprilysin inhibitor), has been approved and prescribed in clinical practice in some of Asian counties (Kario K, Williams B. Hypertens Res. 2022 May 2. Online ahead of print.PMID: 35501475). In this session, I will stress the importance of breaking the chain of hypertension, development of cardiac hypertrophy, and onset of heart failure, as well as sacubitril/valsartan, angiotensin receptor neprilysin inhibitor (ARNI), which is expected to reduce 24-hr blood pressure, including nocturnal hypertension, from an earlier stage.